TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07755150: A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Study Assessing the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes Mellitus.

Sponsor: Chendu DIAO Pharmaceutical Group CO., LTD. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 272 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT07755150 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07755150 Rescue Dossier →